Earnings per share for the last twelve months: Delcath Systems Inc (DCTH)
Due to its monopoly position in the treatment of metastatic melanoma, Delcath Systems, Inc. (DCTH) possesses significant pricing power. The 12-month net income per share history illustrates the dynamics of this process, where 0.15 captures a new level. The company leverages physician confidence in its unique liver perfusion system, scaling the business through the sale of high-margin consumables.
Analytical breakdowns and data insights for company Delcath Systems Inc (DCTH)
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Total Debt to Capital Delcath Systems, Inc.|DCTH - Long-Term Liabilities to Capital|Short-Term Debt to Equity Delcath|DCTH - Company Debts|Debts to Book Capitalization Delcath Systems, Inc.|DCTH - Company Long-Term Liabilities|Company Short-Term Debts Delcath Systems|Quick Liquidity Indicator delcath.com
- net income and valuation multiples indicators:
DCTH - Profit After Payment of Taxes|Projected Future Earnings Delcath Systems, Inc.|DCTH - Company Value to Net Income|Projected Price to Earnings Delcath Systems|DCTH - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Delcath Systems, Inc.|DCTH - Operating income before deduction of amortization|Net earnings per share for the last 12 months Delcath Systems|DCTH - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months delcath.com|DCTH - Expected net earnings per share growth this year|Expected earnings per share growth for next year Delcath Systems, Inc.
Fundamental company valuation:Delcath Systems, Inc. (DCTH)
Delcath Systems, Inc. (DCTH) transition toward the commercialization of the HEPZATO KIT system shifts the company from the clinical development stage to a phase of real revenue generation. The TTM net income per share captures the total annual financial result distributed across all outstanding shares, allowing investors to assess the business's actual viability and expansion rates while filtering out market noise through the analysis of this chart.
Competitor analysis
ONC: Net earnings per share for the last 12 months|HALO - Net earnings per share (EPS TTM)|Revolution Medicines, Inc. (RVMD) - Earnings per share for the last twelve months|Ascentage Pharma Group International - Earnings per share for the trailing year|CGON (CG Oncology Corp) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months UroGen Pharma Corp URGN|Net earnings per share (EPS TTM) BCAX|personalis.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) ERAS (Erasca)|Y-mAbs Therapeutics Inc (YMAB) - Net earnings per one share for the last twelve months|AURA - Earnings per share for the last twelve months|CADL: Earnings per share for the last twelve months|ARAY: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months SELLAS Life Sciences Group|ACTU (Actuate Therapeutics) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Citius Oncology Inc.|Net earnings per share for the last 12 months HURA (TuHURA Biosciences, Inc.)|Earnings per share for the last four quarters TARA|Net earnings per share (EPS TTM) FATE (Fate Therapeutics, Inc.)|Earnings per share for the trailing year WHWK|TCRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year CSBR (Champions Oncology)|xbiotech.com (XBIT) - Earnings per share for the last twelve months|CVM - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months OSTX|Net earnings per one share for the last twelve months radiopharmtheranostics.com RADX|Earnings per share for the last twelve months Artiva Biotherapeutics, Inc. (ARTV)|Net earnings per share for the last four quarters adlainortye.com|Veru Pharma - Net earnings per share for the last 12 months|Earnings per share for the last four quarters TPST (Tempest Therapeutics Corp)|Xilio - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Renovaro Inc.|muraloncology.com (MURA) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months Kairos Pharma|Earnings per share for the last twelve months OnKure Therapeutics, Inc.|CytoMed (GDTC) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months CRIS (Curis, Inc.)|APLM (apollomicsinc.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) THAR (Tharimmune)|Net earnings per share for the last four quarters Advanced Biomed Inc. (ADVB)|GNPX - Earnings per share for the last twelve months|CLDI (Calidi Biotherapeutics) - Earnings per share for the last 12 months|SBFM: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Xenetic Biosciences, Inc.|Net earnings per share for the last 12 months SLRX|Purple Biotech Ltd (PPBT) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) AONC|BeiGene Ltd - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) CKPT (Checkpoint Therapeutics)|ELEV - Net earnings per share for the last 12 months|ICAD: Net earnings per share for the last 12 months|Ikena Oncology, Inc. - Earnings per share for the last four quarters|NTBL: Net earnings per share (EPS TTM)|Viracta Therapeutics, Inc. - Earnings per share for the trailing year|MOR (MorphoSys AG) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months nayabiosciences.com (NAYA)|Net earnings per share (EPS TTM) AAPGV
